Ignite Creation Date:
2025-12-25 @ 12:04 AM
Ignite Modification Date:
2026-02-26 @ 2:14 AM
Study NCT ID:
NCT02114658
Status:
COMPLETED
Last Update Posted:
2017-08-03
First Post:
2014-04-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-04-15
Start Date Type:
ACTUAL
Primary Completion Date:
2015-02-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-08-02
Completion Date Type:
ACTUAL
First Submit Date:
2014-04-08
First Submit QC Date:
None
Study First Post Date:
2014-04-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-08-01
Last Update Post Date:
2017-08-03
Last Update Post Date Type:
ACTUAL